var data={"title":"Interferon beta-1b: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Interferon beta-1b: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6380?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=interferon-beta-1b-patient-drug-information\" class=\"drug drug_patient\">see &quot;Interferon beta-1b: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183545\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Betaseron;</li>\n      <li>Extavia</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183546\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Betaseron;</li>\n      <li>Extavia</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183563\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Interferon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183548\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Analgesics and/or antipyretics may help decrease flu-like symptoms on treatment days:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>US labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple sclerosis (relapsing):</b> SubQ: Initial: 0.0625 mg (2 million units [0.25 mL]) every other day; gradually increase dose by 0.0625 mg every 2 weeks to a target dose of 0.25 mg (8 million units [1 mL]) every other day. <b>Note:</b> In clinical trials involving patients with a single clinical event suggestive of MS, dose titration occurred at weekly intervals (Kappos 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Canadian labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple sclerosis (relapsing):</b> SubQ: Initial: 0.0625 mg (2 million units [0.25 mL]) every other day; gradually increase dose by 0.0625 mg every week to a target dose of 0.25 mg (8 million units [1 mL]) every other day. May titrate more slowly if significant adverse reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple sclerosis (secondary progressive):</b> SubQ: Initial: 0.125 mg (4 million units [0.5 mL]) every other day for 2 weeks, then increase to target dose of 0.25 mg (8 million units [1 mL]) every other day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183549\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897901\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897902\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183526\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Betaseron: 0.3 mg [contains albumin human]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extavia: 0.3 mg [contains albumin human]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183511\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46582539\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The Extavia diluent syringe cap may contain latex.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874832\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Betaseron: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103471s5157lbl.pdf#page=17&amp;token=XrZkkQioGOf0EMrvJeuyTUq6/Q0to/txWBW26yKHR3gh8QTVEdj8UN/KrRzFqcRpwR8GDfxScj3zSjOPrESPdo8Hy3tCC/LCTe4mNJEbg45VDpG6wwOxR3B7GZ9erlDM&amp;TOPIC_ID=8566\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103471s5157lbl.pdf#page=17</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Extavia: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125290s062lbl.pdf#page=16&amp;token=d/CTJ1lvsXrYqtQkgRWBEZ7yePoJ96xGF4Mob6yaGz74NQFxjYstit4gdCjFPT3EiCwUPeR5z685uxMUAf7X85G3HyRQHmYWnq2q2wX6ZzvyBVcUV8hCsoeG+c9WhaDN&amp;TOPIC_ID=8566\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125290s062lbl.pdf#page=16</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183528\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For SubQ administration. The first injection should be administered under the supervision of a health care professional. Withdraw dose of reconstituted solution from the vial into a sterile syringe fitted with needle provided in manufacturer packaging (refer to manufacturer labeling for appropriate size) and inject the solution subcutaneously. The Betaconnect autoinjector may be used with prepared Betaseron syringes after health care provider selects proper depth setting and injection technique (see prescribing information for more detailed use of autoinjector). Sites for self-injection include outer surface of the arms, abdomen (<b>except</b> 2-inch area around the navel), buttocks, and thighs. If patient is very thin, only use the thigh or outer surface of arms. Rotate SubQ injection site. Do not inject into area where skin is bruised, infected, or broken. Patient should be well hydrated. If a dose is missed, administer as soon as remembered; do not administer on 2 consecutive days. Time subsequent doses every 48 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183527\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis:</b> Treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations. Efficacy has also been demonstrated in patients experiencing a first clinical episode and who have MRI features consistent with multiple sclerosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional use (not in US labeling): Treatment of secondary progressive MS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183518\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (12% to 15%), chest pain (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (50% to 57%), pain (42% to 51%), hypertonia (40% to 50%), myasthenia (46%), chills (21% to 25%), dizziness (24%), insomnia (21% to 24%), ataxia (17% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (21% to 24%), dermatological disease (10% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (27%), constipation (20%), diarrhea (19%), abdominal pain (16% to 19%), dyspepsia (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary urgency (11% to 13%), uterine hemorrhage (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphocytopenia (86% to 88%), leukopenia (13% to 18%), neutropenia (13% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (&le;45%; neutralizing; significance not known)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (78% to 85%; including inflammation [53%], pain [18%], tissue necrosis [4% to 5%], hypersensitivity reaction [4%], swelling [2% to 3%], residual mass [2%])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (53% to 61%), arthralgia (31%), myalgia (23% to 27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (decreases over treatment course; 57% to 60%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (31% to 36%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Vasodilatation (8%), hypertension (6% to 7%), peripheral vascular disease (6%), palpitations (4%), tachycardia (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (10%), malaise (6% to 8%), nervousness (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (8%), alopecia (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypermenorrhea (8%), dysmenorrhea (7%), weight gain (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Impotence (8% to 9%), cystitis (8%), urinary frequency (7%), pelvic pain (6%), prostatic disease (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphadenopathy (6% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&gt;5 x baseline: 10% to 12%), increased serum AST (&gt;5 x baseline: 3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Leg cramps (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (6% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, anaphylaxis, anemia, anorexia, apnea, asthma, ataxia, autoimmune hepatitis, blindness, bronchospasm, capillary leak syndrome (in patients with preexisting monoclonal gammopathy), cardiac arrhythmia, cardiomegaly, cardiomyopathy, cerebral hemorrhage, cholecystitis, coma, confusion, convulsion, deep vein thrombosis, delirium, depersonalization, depression, diabetes mellitus, diabetes insipidus, emotional lability, erythema nodosum, esophagitis, ethanol sensitization, exfoliative dermatitis, gastrointestinal hemorrhage, hallucinations, hematemesis, hemolytic-uremic syndrome, hepatic failure, hepatic injury, hepatitis, hepatomegaly, hepatotoxicity (idiosyncratic) (Chalasani 2014), hypercalcemia, hyperglycemia, hyperthyroidism, hyperuricemia, hypocalcemia, hypoglycemia, hypothermia, hypothyroidism, increased gamma-glutamyl transferase, increased serum bilirubin, increased serum triglycerides, lupus erythematosus, maculopapular rash, manic behavior, myocardial infarction, nephrolithiasis, pancreatitis, paresthesia, pericardial effusion, pneumonia, pruritus, psoriasis, psychosis, pulmonary embolism, pulmonary hypertension (Govern 2015; Health Canada Nov. 2, 2016), renal disease (nephritic syndrome), sepsis, shock, skin discoloration, skin photosensitivity, suicidal ideation, syncope, SIADH, thrombocytopenia, thrombotic thrombocytopenic purpura, thyroid dysfunction, tongue edema, tremor, urinary tract infection, urosepsis, urticaria, vaginal hemorrhage, vasculitis, vesiculobullous dermatitis, vomiting, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183531\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">History of hypersensitivity to natural or recombinant interferon beta, albumin (human), or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for interferons is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindication (not in US labeling): Pregnancy, decompensated liver disease (Betaseron, Extavia); current severe depression and/or suicidal ideation (Extavia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183515\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Allergic reactions (eg, bronchospasm, dyspnea, skin rash, tongue edema, urticaria), including anaphylaxis (rare), have been reported with use; discontinue use if anaphylaxis occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-induced lupus erythematosus: Cases of drug-induced lupus erythematosus have been reported with some interferon beta products; signs and symptoms include nephritis, polyarthritis, rash, Raynaud phenomenon, and serositis. Positive serologic testing, including positive anti-nuclear and/or anti-double-stranded DNA antibody testing, may occur; discontinue treatment if signs and symptoms of drug-induced lupus erythematosus develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flu-like symptoms: Associated with a high incidence of flu-like adverse effects; use of analgesics and/or antipyretics on treatment days may be helpful. Improvement in symptoms occurs over time.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Has been reported with beta interferons, including rare reports of hepatitis (autoimmune) and hepatic failure requiring transplant; use with caution in patients with concurrent exposure to other hepatotoxic drugs. Monitor liver function tests as clinically necessary. Consider discontinuation if serum transaminase levels increase significantly or are associated with clinical symptoms (eg, jaundice).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site reactions: Severe injection site reactions (necrosis) may occur which may or may not heal with continued therapy; reactions generally arise within the first 4 months of therapy, but have occurred &ge;1 year after initiation. Incidence of reactions tend to improve over time. Patient and/or caregiver competency in injection technique should be confirmed and periodically re-evaluated. Do not inject into affected area until completely healed; if multiple lesions occur, discontinue use until they are fully healed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leukopenia: Leukopenia has been observed; routine monitoring of complete blood counts with differentials is recommended. Dose reduction may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric disorders: Interferons have been associated with severe psychiatric adverse events (psychosis, mania, depression, suicidal behavior/ideation) in patients with and without previous psychiatric symptoms. Avoid use in severe psychiatric disorders and use caution in patients with a history of depression; patients exhibiting symptoms of depression should be closely monitored and discontinuation of therapy should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic microangiopathy: Cases of thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS) (some fatal) have been reported with interferon beta products. Some cases may occur after several years of therapy. Monitor for new onset hypertension, thrombocytopenia, or impaired renal function; discontinuation of therapy and prompt treatment may be necessary if TTP/HUS are confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Use with caution in patients with bone marrow suppression; may require increased monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with preexisting cardiovascular disease. Rare cases of new-onset cardiomyopathy and/or HF have been reported. If HF worsens in the absence of another etiology, consider discontinuation of therapy. In a scientific statement from the American Heart Association, interferon has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment or in combination with alcohol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Thyroid abnormalities may develop with use; may worsen pre-existing thyroid conditions. Monitor thyroid function tests every 6 months or as clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Contains albumin, which may carry a remote risk of transmitting Creutzfeldt-Jakob or other viral diseases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Some dosage forms may contain natural rubber latex.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299524\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183520\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8566&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183522\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183535\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Spontaneous abortions were reported in 4 women during a clinical trial. Women with multiple sclerosis are generally recommended to discontinue therapy prior to conception (Lu 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183536\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if interferon beta-1b is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183524\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Complete blood chemistries (including platelet count) and liver function tests are recommended at 1, 3, and 6 months following initiation of therapy and periodically thereafter. Thyroid function should be assessed every 6 months in patients with history of thyroid dysfunction or as clinically necessary. Monitor for flu-like symptoms, allergic or anaphylactic reactions, injection-site reactions, worsening of cardiac symptoms (in HF patients); and for sign/symptoms of depression.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183514\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferon beta-1b differs from naturally occurring human protein by a single amino acid substitution and the lack of carbohydrate side chains; mechanism in the treatment of MS is unknown; however, immunomodulatory effects attributed to interferon beta-1b include enhancement of suppressor T cell activity, reduction of proinflammatory cytokines, down-regulation of antigen presentation, and reduced trafficking of lymphocytes into the central nervous system. Improves MRI lesions, decreases relapse rate, and disease severity in patients with secondary progressive MS.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183530\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Limited data due to small doses used </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 8 minutes to 4.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1-8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183534\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Betaseron Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg (1): $609.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Extavia Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg (1): $504.35</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183537\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Betaferon (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, ZA);</li>\n      <li>Emaxen (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Extavia (AT, AU, BB, BE, CZ, DK, EE, ES, FR, GB, GR, HR, HU, IE, IT, LT, LV, MT, NL, NO, PL, PT, RO, SE, SI, TR);</li>\n      <li>Uribeta (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Betaseron (interferon beta-1b) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betaseron (interferon beta-1b) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Extavia (interferon beta-1b) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Extavia (interferon beta-1b) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goodin DS, Frohman EM, Garmany GP, et al, &ldquo;Disease Modifying Therapies In Multiple Sclerosis: Report Of The Therapeutics And Technology Assessment Subcommittee Of The American Academy Of Neurology And The MS Council For Clinical Practice Guidelines,&rdquo; <i>Neurology</i>, 2002, 58:169-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/11805241 /pubmed\" target=\"_blank\" id=\"11805241 \">11805241 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26008947\"></a>Govern EM, Judge EP, Kavanagh E, Gaine S, Lynch T. Interferon beta related pulmonary arterial hypertension; an emerging worrying entity? <i>Mult Scler Relat Disord</i>. 2015;4(3):284-286.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/26008947/pubmed\" target=\"_blank\" id=\"26008947\">26008947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healthy Canadians Recalls &amp; Alerts. Interferon beta products &mdash; assessing the potential risk of plumonary arterial hypertension. Available at http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/interferon-beta2-eng.php. Published November 2, 2016. Accessed November 16, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kappos L, Polman CH, Freedman MS, et al, &ldquo;Treatment With Interferon Beta-1b Delays Conversion to Clinically Definite and Mcdonald MS in Patients With Clinically Isolated Syndromes,&rdquo; <i>Neurology</i>, 2006, 67(7):1242-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/16914693/pubmed\" target=\"_blank\" id=\"16914693\">16914693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lu E, Wang BW, Guimond C, et al, &quot;Disease-Modifying Drugs for Multiple Sclerosis in Pregnancy: A Systematic Review,&quot; <i>Neurology</i>, 2012, 79(11):1130-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/22933738/pubmed\" target=\"_blank\" id=\"22933738\">22933738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sheremata WA, Taylor JR, and Elgart GW, &ldquo;Severe Necrotizing Cutaneous Lesions Complicating Treatment With Interferon Beta-1b,&rdquo; <i>N Engl J Med</i>, 1995, 332(23):1584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/7739724/pubmed\" target=\"_blank\" id=\"7739724\">7739724</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8566 Version 124.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F183545\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F183546\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F183563\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F183548\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F183549\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15897901\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897902\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F183526\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F183511\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46582539\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874832\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F183528\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F183527\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F183518\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F183531\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F183515\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299524\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F183520\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F183522\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F183535\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F183536\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F183524\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F183514\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F183530\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F183534\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F183537\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8566|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=interferon-beta-1b-patient-drug-information\" class=\"drug drug_patient\">Interferon beta-1b: Patient drug information</a></li></ul></div></div>","javascript":null}